Tuesday, November 24, 2020 2:21:22 AM
Google search "MACIVIVA" see how this unknown otc SEC Filer microcap, MYMX led a consortium of 5 european companies including Catalent UK (NYSE: CTLT), Bachem (SWX: BANB), to successfully develop this process. This breakthrough platform is currently applied to the company's HIV vaccine in partnership with University of Louisiana, Lafayette's Iberia Research Center under NIH funding as well as its current in-house covid vaccine development program. The company is also in partnership with Baylor College of Medicine in developing a covid vaccine. News is imminent on status updates.
Recent ALT News
- Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 • GlobeNewswire Inc. • 05/28/2026 03:00:00 PM
- Altimmune to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/27/2026 12:30:00 PM
- New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:15:13 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/13/2026 08:17:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:13:42 PM
- Altimmune shares climb after first-quarter loss beats expectations (ALT) • IH Market News • 05/13/2026 01:29:02 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:34:07 AM
- Altimmune Announces First Quarter 2026 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 • GlobeNewswire Inc. • 05/13/2026 11:15:00 AM
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 • GlobeNewswire Inc. • 05/06/2026 11:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/01/2026 08:36:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:23:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:20:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:18:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:16:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:13:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:11:03 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/01/2026 08:10:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:08:42 PM
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:05:27 PM
